1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
FUJIFILM Holdings Corporation

FUJIFILM Holdings Corporation

FUJIF
FUJIFILM Holdings CorporationUS flagOther OTC
23.50
USD
- -
- -
28.10BMarket Cap
FUJIFILM Holdings Corporation
FUJIF
(Other OTC)

Recent

price

23.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
1,519.62
1,519.12
1,532.49
1,687.68
1,723.65
1,761.61
1,743.86
1,859.95
1,917.92
1,890.46
1,828.18
2,102.78
792.65
2,459.09
2,653.53
2,789
- -
Revenue per Share
43.77
30.28
37.55
56.02
81.98
83.34
98.76
107.54
108.94
102.06
151.09
175.81
60.83
202.24
216.67
229.91
- -
Basic EPS, GAAP
58.36
9.25
61.88
136.72
124.63
98.37
143.93
137.25
126.46
119.17
246.19
131.56
-31.33
-47.15
-47.14
-132.94
- -
Free Cash Flow per Basic Share
9.21
10.83
12.5
13.33
18.33
22.89
22.65
24.24
26.16
29.25
31.66
35.83
12.78
46.65
46.64
70.08
- -
Dividend per Share
1,314.39
1,373.54
1,397.7
1,436.5
1,498.1
1,586.15
1,739.23
1,852.91
2,009.89
2,125.88
2,287.29
2,421.17
736.51
2,310.32
2,466.44
2,623.5
2,620.34
Book Value per Share
1,002.22
981.96
1,053.37
1,170.84
1,301.54
1,173.42
1,270.46
1,207.68
1,139.26
950.91
1,075.19
1,288.96
494.96
1,695.21
1,865.88
2,239.98
2,237.27
Tangible Book Value per Share
1,459
1,445
1,445
1,446
1,446
1,397
1,332
1,308
1,268
1,225
1,199
1,201
3,607
1,204
1,204
1,204
1,205
Basic Weighted Avg Shares
2,217,084
2,195,293
2,214,696
2,439,953
2,492,605
2,460,383
2,322,163
2,433,365
2,431,489
2,315,141
2,192,519
2,525,773
2,859,041
2,960,916
3,195,828
3,356,969
- -
Sales/Revenue/Turnover
7.58
5.15
5.15
5.77
6.92
7.34
7.42
5.07
8.63
8.06
7.55
9.09
9.55
9.35
10.33
10.43
- -
Operating Margin (%)
157,094
147,775
141,548
141,440
122,909
124,960
117,635
127,642
129,932
122,653
123,423
132,999
142,215
150,014
150,014
172,371
- -
Depreciation Expense
63,852
43,758
54,266
80,996
118,553
116,402
131,506
140,694
138,106
124,987
181,205
211,180
219,422
243,509
260,951
276,735
- -
Net Income, GAAP
41.01
33.67
37.53
34.8
29.67
26.58
22.65
27.52
26.35
20.87
23.58
21.94
23.1
24.62
22.78
24.89
- -
Effective Tax Rate (%)
2.88
1.99
2.45
3.32
4.76
4.73
5.66
5.78
5.68
5.4
8.26
8.36
7.67
8.22
8.17
8.24
- -
Profit Margin (%)
724,385
629,624
1,014,923
1,165,275
1,320,930
1,159,440
1,354,622
1,196,585
1,028,621
829,196
791,092
745,154
740,785
408,787
455,741
460,761
460,761
Working Capital
119,314
20,334
317,592
314,968
313,045
310,388
434,843
412,502
353,533
555,823
494,297
303,967
325,460
257,939
555,600
702,551
702,551
LT Debt
1,850,871
1,856,484
2,024,786
2,198,223
2,467,416
2,231,997
2,268,058
2,298,706
2,244,841
1,993,757
2,222,157
2,524,940
2,787,860
3,173,315
3,352,682
3,844,385
3,844,385
Total Equity
4.72
3.67
3.21
3.69
4.46
4.85
4.87
3.17
5.55
5.33
4.53
6.06
6.59
5.86
6.36
5.77
- -
Return on Invested Capital (%)
2.51
1.44
1.65
2.43
3.83
3.68
4.05
4.53
3.81
3.41
5.38
6.1
6.69
7.65
7.45
7.03
- -
Return on Capital (%)
3.34
2.24
2.71
3.95
5.59
5.31
5.8
5.94
5.56
4.85
6.78
7.47
7.89
8.96
9.07
9.03
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
254,768
- -
324,462
LT Borrowings
571,872
- -
607,034
LT Finance Leases
96,176
- -
95,517
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,205
- -
1,205
Market Capitalization
4,242,235
3,690,279
3,710,211

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
1,600,471
- -
1,719,033
Cash, Cash Equivalents & STI
160,878
- -
170,553
Accounts Receivable, Net
643,838
- -
742,721
Inventories
600,118
- -
600,796
Total Current Liabilities
1,156,321
- -
1,258,272
Payables & Accruals
- -
- -
- -
ST Debt
254,768
- -
324,462
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.91%
11.64%
14.67%
Free Cash Flow
- -
- -
181.85%
Net Income, GAAP
9.82%
8.93%
6.05%
Sales/Revenue/Turnover
3.39%
8.98%
5.04%
Total Cash Common Dividend
- -
- -
50.18%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
660,759
727,711
766,941
805,505
2,960,916
2025
- -
- -
- -
- -
3,195,828
2026
- -
- -
- -
- -
3,356,969

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
45.25
49.17
50
- -
202.24
2025
- -
- -
- -
- -
216.67
2026
- -
- -
- -
- -
229.91

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
23.35
- -
23.33
- -
46.65
2025
- -
- -
- -
- -
46.64
2026
- -
- -
- -
- -
70.08
Similar Companies
BICO Group AB (publ) (BCCOY)
United Orthopedic Corporation (4129.TWO)
Nanomix Corporation (NNMX)
Treace Medical Concepts, Inc. (TMCI)
iXensor Co., Ltd. (6734.TWO)
Nihon Kohden Corporation (NHNKF)
Business
FUJIFILM Holdings Corporation FUJIFILM Holdings Corporation engages in the development, manufacture, and sale of products and services across healthcare, electronics, business innovation, and imaging segments. The company provides healthcare solutions including medical imaging systems, bio-CDMO services for biologics manufacturing, and life science solutions such as cell culture media and regenerative medicine; electronics materials encompassing semiconductor materials, display materials like optical films for flat-panel displays, and other advanced materials; business innovation offerings comprising business and office solutions including document management and photocopiers, as well as graphic communications equipment and materials; and imaging products such as consumer cameras including Instax instant cameras, professional imaging equipment, photographic films, and lenses. Founded in 1934 and headquartered in Tokyo, Japan, FUJIFILM Holdings Corporation operates globally with consolidated subsidiaries in over 270 companies across regions including North America, Europe, Asia-Pacific, and ASEAN countries, targeting healthcare providers, electronics manufacturers, enterprises, and consumers. Recent developments include the completion of a new advanced semiconductor materials building in Shizuoka in November 2025, the launch of joint research with Japan's National Cancer Center in November 2025 to advance cancer treatments, the planned opening of NURA health screening centers in Vietnam, Thailand, the Philippines, and Malaysia in October 2025, and the May 2023 acquisition of Entegris's semiconductor high-purity process chemicals business for $700 million to strengthen its electronics materials portfolio.